SCHEMBL2269965

SCHEMBL2269965

CC1(C)Oc2cc([N+](=O)[O-])ccc2N(c2cc3c(cc2Cl)OC(F)(F)O3)C1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 10/20 0.36
LMNA P02545 6/20 0.36
MAPT P10636 6/20 0.36
SMN1; SMN2 Q16637 5/20 0.36
MAPK1 P28482 2/20 0.36
NR3C2 P08235 1/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.35
CASP6 P55212 2/20 0.35
POLB P06746 1/20 0.35
APEX1 P27695 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CASP1 P29466 1/20 0.34
CASP3 P42574 1/20 0.34
CASP4 P49662 1/20 0.34
CASP7 P55210 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL758117 0.85 NR3C2 (0.43) GAAMEN1KMT2AALDH1A1LMNA
SCHEMBL756076 0.84 NR3C2 (0.43) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL753893 0.84 NR3C2 (0.37) GAAALDH1A1MAPTSMN1; SMN2NR3C2
SCHEMBL754983 0.80 PKM (0.44) GAAMEN1KMT2AALDH1A1LMNA
SCHEMBL755000 0.78 NR3C2 (0.62) GAAMAPK1NR3C2HPGD
SCHEMBL757262 0.76 NR3C2 (0.60) MEN1KMT2AALDH1A1NR3C2CASP6
SCHEMBL754188 0.76 MAPT (0.46) GAAMEN1KMT2AALDH1A1LMNA
SCHEMBL2264897 0.74 NR3C2 (0.42) GAAMEN1KMT2AALDH1A1LMNA
SCHEMBL759695 0.73 NR3C2 (0.45) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL9230962 0.72 ALDH1A1 (0.43) MEN1KMT2AALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188073-B2 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20110251185-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS IIJIMA TORU 2011-10-13 US disclosed
US-7998956-B2 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-16 US disclosed
US-20090023716-A1 Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-22 US disclosed
EP-1984345-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-10-29 EP disclosed
WO-2007089034-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023716-A1 Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents NR3C2, MC2R, NR3C1 GAA 4858/4885MEN1 1447/4885KMT2A 2504/4885
US-20110251185-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS NR3C2, MC2R, NR3C1 GAA 4858/4885MEN1 1447/4885KMT2A 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.